구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | ciprofloxacin (ciprofloxacin) Laboratorios Sophia S.A de C.V.·Brain and Central Nervous System T… 60 trials·t½ 2.52 h |
|---|---|
Overview Program | ciprofloxacin |
Overview Company | Laboratorios Sophia S.A de C.V. |
Overview Modality | CGT |
Overview Target | Brain and Central Nervous System Tumors |
Overview Indication | Brain and Central Nervous System Tumors; Lymphoma |
Overview Phase | PHASE_3 |
Overview Status | ACTIVE |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
PK/PD Half-life | 2.52 h |
PK/PD Species | Rabbit |
PK/PD Animal (cat.) | Unknown |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Rabbit |
Toxicology Animal (cat.) | Unknown |
Toxicology Major finding | Restoring ciprofloxacin efficacy via β-caryophyllene synergy for concurrent infection control and tissue regeneration.. The occurrence of antimicrobial-resistant microbial infection on the wounds are considered a critical issue in delayed or non-healing wounds. Due to the scarcity of new antibiotics in the market, alternate combinational therapies are gaining interest in tackling this issue.… |
Clinical Safety signal | Restoring ciprofloxacin efficacy via β-caryophyllene synergy for concurrent infection control and tissue regeneration.. The occurrence of antimicrobial-resistant microbial infection on the wounds are considered a critical issue in delayed or non-healing wounds. Due to the scarcity of new antibiotics in the market, alternate combinational therapies are gaining interest in tackling this issue.… |
Clinical Selected reported efficacy | ORR 6% |
Clinical Reported ORR | 15% |
Clinical Reported PFS | 4.7 |
Clinical Reported OS | 11.2 |
Clinical Result source | ClinicalTrials.gov NCT00332163 |
Clinical Program phase | PHASE_3 |
Clinical Trial ref | NCT00332163 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | ciprofloxacin (ciprofloxacin) Laboratorios Sophia S.A de C.V.·Brain and Central Nervous System T… 60 trials·t½ 2.52 h |
|---|---|
Overview Program | ciprofloxacin |
Overview Company | Laboratorios Sophia S.A de C.V. |
Overview Modality | CGT |
Overview Target | Brain and Central Nervous System Tumors |
Overview Indication | Brain and Central Nervous System Tumors; Lymphoma |
Overview Phase | PHASE_3 |
Overview Status | ACTIVE |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
PK/PD Half-life | 2.52 h |
PK/PD Species | Rabbit |
PK/PD Animal (cat.) | Unknown |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Rabbit |
Toxicology Animal (cat.) | Unknown |
Toxicology Major finding | Restoring ciprofloxacin efficacy via β-caryophyllene synergy for concurrent infection control and tissue regeneration.. The occurrence of antimicrobial-resistant microbial infection on the wounds are considered a critical issue in delayed or non-healing wounds. Due to the scarcity of new antibiotics in the market, alternate combinational therapies are gaining interest in tackling this issue.… |
Clinical Safety signal | Restoring ciprofloxacin efficacy via β-caryophyllene synergy for concurrent infection control and tissue regeneration.. The occurrence of antimicrobial-resistant microbial infection on the wounds are considered a critical issue in delayed or non-healing wounds. Due to the scarcity of new antibiotics in the market, alternate combinational therapies are gaining interest in tackling this issue.… |
Clinical Selected reported efficacy | ORR 6% |
Clinical Reported ORR | 15% |
Clinical Reported PFS | 4.7 |
Clinical Reported OS | 11.2 |
Clinical Result source | ClinicalTrials.gov NCT00332163 |
Clinical Program phase | PHASE_3 |
Clinical Trial ref | NCT00332163 |
추천 비교
추천 비교